SpiceJet Scion Urges India to Open Vaccination to Private Sector
(Bloomberg) -- Avani Singh, the chief executive officer of SpiceHealth and daughter of SpiceJet Ltd. Chairman Ajay Singh, has called upon India's government to open up the manufacture and procurement of vaccines to the private sector, saying it's the only way to ensure the nation's vast population receives adequate protection from the pandemic.
“The government needs to become much more lenient in opening up vaccination to the private sector,” Singh said in an interview last week. “We are obviously moving at a much slower pace with vaccinations than we should be. If they let private players like labs and hospitals procure vaccines from Pfizer, Moderna and let private players make Covaxin more aggressively we could significantly ramp up the administration and build up enough immunity to get out of this faster. Not allowing labs and hospitals to procure and facilitate vaccines is a huge untapped potential.”
India is suffering the world's worst Covid-19 outbreak and its health care system is collapsing as it runs short of everything from hospital beds to oxygen cylinders. Although the South Asian nation is one of the world's biggest vaccine makers, supply locally has run dry amid an expansion of access to everyone aged 18 and above.
To date, India's public health care operators have done nearly all the heavy lifting in treating Covid patients. When fatigue started setting in among workers at state-run hospitals, Mumbai, one of the country's largest and most-populated cities, invoked a colonial era law to rope in private-sector doctors. Vaccine purchases were also fully controlled by the federal government when only people aged 45 and above were eligible.
Mobile Labs
“It was criminal what was going on around the country,” Singh said, adding she was getting at least 30 calls a day from people asking for beds, oxygen concentrators and tests because it was taking four days to even get a slot for testing followed by another week for results to come in and people with symptoms weren't able to get treated without a positive report. “The general perception in the country was we're done, Covid is gone and that was an incorrect perception to have. To a certain extent it was avoidable and to a large extent we were just not equipped for it.”
SpiceHealth was founded in November last year, a time when parent company SpiceJet Ltd., India's second-largest airline, was hard hit by the pandemic. So much red ink has prompted airlines around the world to look for new revenue streams as they burn through cash. SpiceJet began selling Covid tests for around $4 to passengers to get them back on planes. Low-cost travel pioneer AirAsia Group Bhd. has embraced a similar diversification strategy, expanding its digital operations with an app that can be used for shopping, booking flights and ordering food.
SpiceHealth quickly became a first mover in cheap testing, rolling out 499 rupee ($6.90) Covid tests -- one-fifth the then market rate in Delhi. That price is now largely the industry standard. SpiceHealth was also the first to set up mobile labs that can be quickly erected and moved as need be. There are now 15 SpiceHealth mobile labs across five states and each can process as many as 3,000 samples a day.
“We got a lot of backlash from private players when we came up with 499 rupee tests,” Singh said. “It's really about breaking that chain of pricing far above cost and you can recover a lot of that margin with scale. The mobile testing lab model is disruptive and very effective. There are underserved areas around the country where it's very difficult to ramp up a fixed facility, find manpower and sustain it over a long period of time. With a mobile lab we can provide instant numbers and cover clusters where the need is the highest.”
Singh said SpiceHealth, which is profitable and debt-free, would like to offer an end-to-end solution from procurement to transportation and administration of shots and reach remote areas but procuring vaccines as a private company has been a challenge.
“The biggest bottleneck with vaccines is the procurement, getting hold of companies that will sell directly to the private sector. That's the challenge most companies that are trying to get involved are facing,” she said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.